Loading...

OTC Markets

Totals

Securities

12,429

Dollar Vol

$998.0M

Share Vol

1.7B

Trades

107,372

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

Market Activity
Stock
BSSP
Overview

BSSP
Bassline Productions, Inc.

Common Stock

Warning! This security is eligible for Unsolicited Quotes Only

This stock is not eligible for proprietary broker-dealer quotations. All quotes in this stock reflect unsolicited customer orders. Unsolicited-Only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.

Warning! This security is traded on the Expert Market

The Expert Market^® serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing. OTC Markets Group may designate securities for quoting on the Expert Market when it is not able to confirm that the company is making current information publicly available under SEC Rule 15c2-11, or when the security is otherwise restricted from public quoting. See additional information about the Expert Market here.

Open

N/A

Daily Range

N/A

Volume

N/A

Dividend

N/A

Real-Time Level 2 Quote

Bid

Ask

MPID MPID	Bid Price Bid Price	Time Time
ETRF	24.90	>year
CDEL	21.92	03/16
MACM	18.95	>year
NITE	18.95	>year
CSTI	18.55	>year

MPID MPID	Ask Price Ask Price	Time Time
INTL	19.40	>year
NITE	19.40	>year
MACM	19.43	>year
MAXM	20.11	>year
CANT	22.05	>year

No Real Time Level 2 Quotes Available on Expert Tier

Trade Data

News

Filings and Disclosure

Company Description

The Company as of 2021 is now in process of seeking a merger or acquisition candidate and working to bring the Company current. Effective October 9, 2017 the PSA Agreement with Canteck Pharma, inc. was rescinded do inability to proceed with the license for Mexico that previously had focused on its immunotherapeutic based technology specific to Cancer indication.

Videos